Argenica Therapeutics Ltd
AGN
Company Profile
Business description
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Contact
117 Broadway
Unit 4
NedlandsWA6009
AUST: +61 893293396
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,677.73 | 87.38 | -1.13% |
| DAX 40 | 23,420.23 | 351.22 | -1.48% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,840.69 | 44.23 | -0.50% |
| HKSE | 23,892.56 | 142.82 | -0.59% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,834.25 | 338.84 | -0.89% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,377.00 | 25.66 | -0.75% |